Matthew Stanton
Stock Analyst at Jefferies
(0.08)
# 4,505
Out of 5,150 analysts
8
Total ratings
20%
Success rate
-27.41%
Average return
Main Sectors:
Stocks Rated by Matthew Stanton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Buy | $42 → $40 | $25.13 | +59.17% | 3 | Feb 4, 2026 | |
| RGEN Repligen | Maintains: Hold | $145 → $135 | $125.84 | +7.28% | 1 | Sep 12, 2025 | |
| CYRX Cryoport | Downgrades: Hold | $20 → $8 | $8.74 | -8.47% | 2 | Aug 7, 2024 | |
| LAB Standard BioTools | Initiates: Buy | $3.25 | $1.06 | +206.60% | 1 | Apr 4, 2024 | |
| BLFS BioLife Solutions | Initiates: Buy | $22 | $20.67 | +6.43% | 1 | Apr 4, 2024 |
Azenta
Feb 4, 2026
Maintains: Buy
Price Target: $42 → $40
Current: $25.13
Upside: +59.17%
Repligen
Sep 12, 2025
Maintains: Hold
Price Target: $145 → $135
Current: $125.84
Upside: +7.28%
Cryoport
Aug 7, 2024
Downgrades: Hold
Price Target: $20 → $8
Current: $8.74
Upside: -8.47%
Standard BioTools
Apr 4, 2024
Initiates: Buy
Price Target: $3.25
Current: $1.06
Upside: +206.60%
BioLife Solutions
Apr 4, 2024
Initiates: Buy
Price Target: $22
Current: $20.67
Upside: +6.43%